Back to top
more

Bayer (BAYRY)

(Delayed Data from OTC)

$7.72 USD

7.72
2,121,650

+0.07 (0.92%)

Updated May 31, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (157 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

4 Reasons to Add Regeneron (REGN) Stock to Your Portfolio

by Zacks Equity Research

Regeneron (REGN) is expected to gain from a solid and diverse portfolio despite stiff competition for its key drugs. The promising pipeline also sets the stage for growth further.

4D Molecular (FDMT) to Start Studies on Cystic Fibrosis, Wet AMD

by Zacks Equity Research

4D Molecular (FDMT) is set to initiate studies for gene-therapy candidates to treat cystic fibrosis lung disease and wet AMD, following FDA clearance of its two IND applications.

Regeneron's (REGN) sBLA for Libtayo Gets Priority Review

by Zacks Equity Research

Regeneron's (REGN) application seeking the label expansion of PD-1 inhibitor Libtayo for the treatment of patients with recurrent or metastatic cervical cancer has been granted Priority Review.

Merck (MRK) Keytruda Meets Hepatocellular Carcinoma Study Goal

by Zacks Equity Research

Merck's (MRK) Keytruda achieves both primary and secondary endpoints in a phase III study evaluating the drug in patients with advanced hepatocellular carcinoma.

BELLUS (BLU) Completes Enrollment in Two Mid-Stage Studies

by Zacks Equity Research

BELLUS (BLU) completes enrollment in the mid-stage studies for refractory chronic cough and chronic pruritus associated with atopic dermatitis.

Exelixis (EXEL) Gets FDA Nod for Cabometyx for Thyroid Cancer

by Zacks Equity Research

Exelixis (EXEL) gets FDA approval for a label expansion of Cabometyx for the treatment of locally advanced or metastatic differentiated thyroid cancer.

REGENXBIO (RGNX) Stock Up on Collaboration Deal With AbbVie

by Zacks Equity Research

REGENXBIO (RGNX) enters into a strategic partnership with AbbVie to co-develop and commercialize RGX-314, a potential gene therapy for retinal indications. Resultantly, REGENXBIO's share price surges.

Kinjel Shah headshot

Pharma Stock Roundup: SNY to Buy Kadmon, New Approvals for AZN & MRK's Drugs

by Kinjel Shah

Sanofi (SNY) offers $1.9 billion to buy Kadmon Holdings to strengthen its transplant business. AstraZeneca's (AZN) Ultomiris and Merck's (MRK) Keytruda get approvals for expanded use.

Bayer's (BAYRY) Chronic Cough Candidate Meets Efficacy Goal

by Zacks Equity Research

Bayer (BAYRY) posts positive data from the phase IIb PAGANINI study which is evaluating its investigational candidate, eliapixant, in patients with refractory chronic cough.

Kinjel Shah headshot

Pharma Stock Roundup: PFE's COVID Jab Full Approval by FDA, JNJ's Booster Data

by Kinjel Shah

FDA approves Pfizer's (PFE) BLA for COVID-19 vaccine, Comirnaty. J&J (JNJ) released data supporting use of the booster shot.

Regeneron's (REGN) Wet AMD Study on High Dose Eylea Meets Goal

by Zacks Equity Research

Regeneron's (REGN) phase II study evaluating a higher 8-mg dose of Eylea injection in patients with wet age-related macular degeneration has met the primary safety endpoint.

The Zacks Analyst Blog Highlights: Chevron, T-Mobile, American Express, Vale and Bayer

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Chevron, T-Mobile, American Express, Vale and Bayer

Sheraz Mian headshot

Top Analyst Reports for Chevron, T-Mobile & American Express

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation (CVX), T-Mobile US, Inc. (TMUS), and American Express Company (AXP).

Bayer's (BAYRY) Q2 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Bayer (BAYRY) beats estimates for both earnings and revenues in the second quarter of 2021.

Kinjel Shah headshot

Pharma Stock Roundup: LLY, NVO, BAYRY Q2 Earnings, SNY's TBIO Buyout, FDA Updates

by Kinjel Shah

Lilly (LLY), Novo Nordisk (NVO) and Bayer (BAYRY) announce Q2 results. FDA approves AstraZeneca's (AZN) lupus medicine, Saphnelo. Sanofi (SNY) to buy Translate Bio.

Regeneron (REGN) Q2 Earnings Beat, REGEN-COV Boosts Performance

by Zacks Equity Research

Regeneron (REGN) beats on Q2 earnings while sales record strong year-over-year growth on solid performance of Dupixent and Eylea, and significant contribution from REGEN-COV.

Bayer Aktiengesellschaft (BAYRY) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Bayer Aktiengesellschaft (BAYRY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Merck (MRK) Heart Failure Drug Verquvo Gets Approval in Europe

by Zacks Equity Research

Merck (MRK)/Bayer's (BAYRY) vericiguat gets approval for symptomatic chronic heart failure in patients with reduced ejection fraction in Europe.

Bayer's (BAYRY) Parkinson's Disease Therapy Gets Fast Track Tag

by Zacks Equity Research

The FDA grants a Fast Track status to Bayer's (BAYRY) DA01 cell therapy which is being developed for the treatment of Parkinson's disease.

Lilly (LLY), Incyte's Decision on Olumiant sNDA Delayed by FDA

by Zacks Equity Research

The FDA will not meet the PDUFA action date for Lilly (LLY) and Incyte's (INCY) sNDA for Olumaint to treat adults with atopic dermatitis.

Merck (MRK) Gets FDA Nod for Pneumococcal Vaccine Vaxneuvance

by Zacks Equity Research

Merck's (MRK) 15-valent pneumococcal conjugate vaccine, Vaxneuvance includes pneumococcal serotypes, 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.

Kinjel Shah headshot

Pharma Stock Roundup: NVO & LLY's Small Acquisitions, JNJ's Sunscreens Recall

by Kinjel Shah

Novo Nordisk (NVO) and Eli Lilly (LLY) announce small acquisition deals. J&J (JNJ) recalls some consumer products.

TFF Pharmaceuticals (TFFP) Completes Enrollment in Phase I Study

by Zacks Equity Research

TFF Pharmaceuticals (TFFP) completes enrollment in the phase I study on tacrolimus inhalation powder and announces positive preliminary data.

AstraZeneca (AZN) Gets Clearance in UK for Alexion Acquisition

by Zacks Equity Research

AstraZeneca (AZN) obtains UK Competition and Markets Authority's permission for the impending acquisition of Alexion. The deal is expected to close on Jul 21, 2021.

Biogen (BIIB) In-Licenses Rights to Multiple Sclerosis Drug

by Zacks Equity Research

Biogen partners with InnoCare Pharma for orelabrutinib, a BTK inhibitor with the potential of treating multiple sclerosis. The drug is currently undergoing phase II study.